These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38721980)

  • 21. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
    Borghetti A; Lombardi F; Gagliardini R; Baldin G; Ciccullo A; Moschese D; Emiliozzi A; Belmonti S; Lamonica S; Montagnani F; Visconti E; De Luca A; Di Giambenedetto S
    BMC Infect Dis; 2019 Jan; 19(1):59. PubMed ID: 30654739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.
    Girard PM; Antinori A; Arribas JR; Ripamonti D; Bicer C; Netzle-Sveine B; Hadacek B; Moecklinghoff C
    HIV Med; 2017 Jan; 18(1):5-12. PubMed ID: 27279571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience.
    Gazzola L; Cicconi P; Ripamonti D; Di Filippo E; Gustinetti G; Di Biagio A; Marchetti G; Bini T; d'Arminio Monforte A
    HIV Clin Trials; 2014; 15(4):140-50. PubMed ID: 25143023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial.
    Zhao Y; Keene C; Griesel R; Sayed K; Gcwabe Z; Jackson A; Ngwenya O; Schutz C; Goliath R; Cassidy T; Goemaere E; Hill A; Maartens G; Meintjes G
    Wellcome Open Res; 2021; 6():33. PubMed ID: 36017341
    [No Abstract]   [Full Text] [Related]  

  • 26. Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
    Paton NI; Musaazi J; Kityo C; Walimbwa S; Hoppe A; Balyegisawa A; Kaimal A; Mirembe G; Tukamushabe P; Ategeka G; Hakim J; Mugerwa H; Siika A; Asienzo J; Castelnuovo B; Kiragga A; Kambugu A;
    N Engl J Med; 2021 Jul; 385(4):330-341. PubMed ID: 34289276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients.
    Vizcarra P; Fontecha M; Monsalvo M; Vivancos MJ; Rojo A; Casado JL
    Antivir Ther; 2019; 24(6):467-471. PubMed ID: 31172977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
    Waalewijn H; Szubert AJ; Wasmann RE; Wiesner L; Chabala C; Bwakura-Dangarembizi M; Makumbi S; Nangiya J; Mumbiro V; Mulenga V; Musiime V; Monkiewicz LN; Griffiths AL; Bamford A; Doerholt K; Denti P; Burger DM; Gibb DM; McIlleron HM; Colbers A;
    Clin Infect Dis; 2023 Sep; 77(6):875-882. PubMed ID: 37315296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
    Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).
    Ruane P; Alas B; Ryan R; Perniciaro A; Witek J
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1215-9. PubMed ID: 21083412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
    Patel K; Huo Y; Jao J; Powis KM; Williams PL; Kacanek D; Yee LM; Chadwick EG; Shiau S; Jacobson DL; Brummel SS; Sultan-Beyer L; Kahlert CR; Zash R; Seage GR; ;
    N Engl J Med; 2022 Sep; 387(9):799-809. PubMed ID: 36053505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
    Avihingsanon A; Hughes MD; Salata R; Godfrey C; McCarthy C; Mugyenyi P; Hogg E; Gross R; Cardoso SW; Bukuru A; Makanga M; Badal-Aesen S; Mave V; Ndege BW; Fontain SN; Samaneka W; Secours R; Van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Munyanga C; Chagomerana M; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC; Grinsztejn B;
    J Int AIDS Soc; 2022 Jun; 25(6):e25905. PubMed ID: 36039892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study.
    Olliges E; Bührlen B; Fischer F; Boesecke C; Kümmerle T; Schneider J; Weidlich S; Cordes C; Heiken H; Stellbrink HJ; Krznaric I; Scholten S; Jensen BE; Wolf E; Ronel J; Spinner CD; On Behalf Of The Dualis Study Group
    AIDS Care; 2022 Jun; 34(6):698-707. PubMed ID: 33896276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data.
    Sangaré MN; Baril JG; de Pokomandy A; Ferreira Guerra S; Carabali M; Laprise C; Thomas R; Klein M; Tremblay C; Roger M; Pexos C; Greenwald ZR; Machouf N; Durand M; Hardy I; Dakouo M; Trevisan A; Laporte L; Schnitzer ME; Trottier H
    Open Forum Infect Dis; 2020 Nov; 7(11):ofaa404. PubMed ID: 33204746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA).
    Prins HAB; Zino L; Svensson EM; Verbon A; de Bree GJ; Prins JM; Reiss P; Burger DM; Rokx C; Colbers A;
    Int J Antimicrob Agents; 2023 Jan; 61(1):106697. PubMed ID: 36470510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study.
    Winston A; Fätkenheuer G; Arribas J; Hill A; van Delft Y; Moecklinghoff C
    HIV Clin Trials; 2010; 11(3):163-9. PubMed ID: 20736152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.
    Capetti AF; Sterrantino G; Cossu MV; Cenderello G; Cattelan AM; De Socio GV; Rusconi S; Riccardi N; Baldin GM; Cima S; Niero FP; Rizzardini G; Sasset L
    Antivir Ther; 2017; 22(3):257-262. PubMed ID: 27661787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
    Madruga JV; Berger D; McMurchie M; Suter F; Banhegyi D; Ruxrungtham K; Norris D; Lefebvre E; de Béthune MP; Tomaka F; De Pauw M; Vangeneugden T; Spinosa-Guzman S;
    Lancet; 2007 Jul; 370(9581):49-58. PubMed ID: 17617272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.
    Capetti AF; Cossu MV; Orofino G; Sterrantino G; Cenderello G; De Socio GV; Cattelan AM; Soria A; Rusconi S; Riccardi N; Baldin GM; Niero FP; Barbarini G; Rizzardini G
    BMC Infect Dis; 2017 Sep; 17(1):658. PubMed ID: 28964268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.